文献速递甲状腺疾病

多平台分子检测作为细针穿刺评估儿童甲状腺结节的辅助手段

Multiplatform Molecular Testing as an Adjunct to Fine Needle Aspiration in the Evaluation of Pediatric Thyroid Nodules.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

回顾性分析2020年10月至2023年3月Lurie儿童医院37例7至20岁患者的39份甲状腺细针穿刺样本,行ThyGeNEXT®癌基因测序与ThyraMIR®微小RNA风险分类,并与最终手术病理或重复穿刺结果比较。恶性病例最常见突变为BRAFV600E(38%)、RET-PTC1融合(14%)和NRAS突变(14%)。多平台分子检测诊断恶性病理的敏感性为90.5%,特异性为88.9%。

要点

  • 儿童甲状腺结节FNA样本可行癌基因联合miRNA多平台分子检测。
  • 恶性病例中BRAFV600E变异占38%,RET-PTC1融合和NRAS变异各占14%。
  • 多平台分子检测诊断恶性病理的敏感性90.5%、特异性88.9%。

核心结论

  • 这是首项报告儿童队列FNA细胞病理联合癌基因与miRNA分析的研究,多平台分子检测可能是儿童甲状腺结节术前诊断的有用辅助手段。

研究设计与样本

  • 回顾性分析2020年10月至2023年3月Lurie儿童医院采集的存档FNA样本,共纳入39例病例。
  • 研究对象为37例7至20岁患者(平均年龄13.9岁),就诊于转诊中心。
  • 对FNA样本行Interpace Diagnostics®多平台检测,包括ThyGeNEXT®癌基因面板和ThyraMIR® miRNA风险分类器,分子结果与最终手术病理或重复FNA结果比较。

主要发现

  • 恶性病例中最常见的致癌改变为BRAFV600E变异(38%)、RET-PTC1融合(14%)和NRAS变异(14%)。
  • 21份恶性样本中19份为阳性(高风险)miRNA表达谱。
  • 18例良性病例中15例为阴性(低风险)miRNA表达谱。
  • 多平台分子检测检测恶性病理的敏感性为90.5%,特异性为88.9%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Molecular analysis of thyroid cytopathology derived from fine needle aspiration (FNA) improves diagnostic yield and informs presurgical treatment stratification of adults with thyroid nodules. Its use is limited in pediatrics, but it has the potential to guide clinical management for these patients. OBJECTIVE: To report on the results of oncogene sequencing and microRNA (miRNA)-based risk classification of thyroid FNA cytopathology in a pediatric cohort. DESIGN: Retrospective analysis of archived FNA samples collected from patients seen at Lurie Children's Hospital between October 2020 and March 2023; 39 cases were included in the study. SETTING: Referral center. PATIENTS: Thirty-seven patients ages 7 to 20 years (mean age 13.9 years). INTERVENTIONS: Interpace Diagnostics®' multiplatform testing including ThyGeNEXT® (oncogene panel) and ThyraMIR® (miRNA risk classifier) was performed on FNA samples. Molecular results were compared to final surgical pathology or repeat FNA results. MAIN OUTCOME MEASURES: Description of cohort molecular characteristics; test sensitivity and specificity. RESULTS: The most common oncogenic alterations among malignant cases were the BRAFV600E variant (38%), RET-PTC1 fusions (14%), and NRAS variants (14%). Nineteen of 21 malignant samples had positive (high-risk) miRNA expression profiles. Fifteen of 18 benign cases had negative (low-risk) miRNA profiles. Multiplatform molecular testing demonstrated 90.5% sensitivity and 88.9% specificity in detecting malignant pathology. CONCLUSION: This is the first study to report on the use of combined oncogene and miRNA analysis of FNA cytopathology in a pediatric cohort. Multiplatform molecular testing is a potentially useful adjunct to FNA as a presurgical diagnostic tool in the evaluation of pediatric thyroid nodules.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Aekka A, Arva NC, Ren HZ, et al. Multiplatform Molecular Testing as an Adjunct to Fine Needle Aspiration in the Evaluation of Pediatric Thyroid Nodules. J Clin Endocrinol Metab. 2025. PMID: 40037628. doi:10.1210/clinem/dgaf110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。